Retirement Stock Portfolio: 10 Healthcare Stocks to Buy

9. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Number of Hedge Fund Holders: 38     

Bio-Rad Laboratories, Inc. (NYSE:BIO) manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. This company is a great investment prospect due to numerous factors. For example, as per the report for the third quarter of 2024, the company showed a significant increase in net sales driven by the Clinical Diagnostics segment. Reported total net sales were $649.7 million, an increase of 2.8% compared to $632.1 million reported for the third quarter of the prior year. On a currency-neutral basis, quarterly sales increased 3.4% compared to the same period in 2023. In addition, the company also recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $653.2 million on a diluted basis versus a net income of $106.3 million on a diluted basis, reported for the same period of the prior year. Moreover, the company’s collaboration with Allegheny Health Network aims to generate clinical evidence across a range of cancer types to support the implementation of Bio-Rad’s Droplet Digital PCR technology for tumor-informed molecular residual disease (MRD) monitoring of patients with solid tumor cancer following curative-intent treatment.